This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability and bioavailability (exploring absorption of drug in body) of NN9924 in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
155
Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
Novo Nordisk Investigational Site
Harrow, United Kingdom
Number and severity of adverse events (AEs) recorded
Time frame: from dosing to Day 22
The uptake in blood of oral NN9924 compared to i.v. and s.c. administration of the same compound
Time frame: from 0 to 504 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Subjects will be randomized to receive a single dose of placebo.
As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.